Nephrol Dial Transplant (1999) 14: 2710-2713
© 1999 European Renal Association-European Dialysis and Transplant Association
Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels
1 Departments of Internal Medicine I and 2 Surgery, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands
Correspondence and offprint requests to: Dr N. M. van Besouw, University Hospital Rotterdam-Dijkzigt, Department of Internal Medicine I, Room Bd299, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
Background. Both mycophenolate mofetil (MMF) and azathioprine (AZA) are immunosuppressive drugs that inhibit purine synthesis. In theory, MMF selectively inhibits lymphocyte proliferation, while AZA has well-known effects on red blood cells and thrombocytes as well. In renal transplant recipients we replaced CsA therapy by MMF in an attempt to reduce the immunosuppressive load 1 year after kidney transplantation. During this study we observed the effect of MMF on haematological parameters such as haemoglobin (Hb), leukocytes, and thrombocytes.
Methods. One year after kidney transplantation 26 stable patients were converted from cyclosporin A (CsA) to MMF (2 g/day). Thereafter, these patients were tapered twice in their MMF dose from 2 g to 1.5 g (4 months after conversion) and from 1.5 to 1 g (8 months after conversion) per day. The Hb levels, leukocyte and thrombocyte counts, and mycophenolic acid (MPA) trough levels were routinely measured.
Results. After conversion from CsA to MMF not only creatinine levels and the number of leukocytes, but also the haemoglobin (Hb) level significantly decreased in 21/26 patients (P=0.0004). In eight patients the Hb level dropped more than 1 mmol/l (=1.61 g/dl). Only in two of eight patients was an explanation for blood loss found. The effect on Hb level did not ameliorate after the first MMF dose reduction to 1.5 g/day. After tapering the MMF dose to 1 g/day, the Hb approached the pre-conversion level. Not only the MMF dose but also the mycophenolic acid (MPA) trough level correlated with the Hb level.
Conclusions. After conversion from CsA to MMF 1 year after kidney transplantation, a decrease in Hb level and leukocyte count was observed. The MPA trough level correlated also with the Hb level. The effect on the Hb level was reversible after dose reduction. This finding suggests that MMF exerts a negative effect on erythropoietic cells.
Keywords: cyclosporin A; haemoglobin; kidney transplantation; leukocytes; mycophenolate mofetil; mycophenolic acid
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Cattaneo, M. Cortinovis, S. Baldelli, A. Bitto, E. Gotti, G. Remuzzi, and N. Perico Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1147 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Sievers New Antiproliferative Immunosuppressive Agents Journal of Pharmacy Practice, December 1, 2003; 16(6): 401 - 413. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Francois, A. Durrbach, M. Amor, R. Djeffal, F. Kriaa, V. Paradis, P. Bedossa, and B. Charpentier The long-term effect of switching from cyclosporin A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1909 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Neumann, M. Haidinger, H. Jager, H. Grutzmacher, A. Griesmacher, M. M. Muller, P. M. Bayer, and F. Thomas Meisl Pharmacokinetics of Mycophenolate Mofetil in Patients with Autoimmune Diseases Compared Renal Transplant Recipients J. Am. Soc. Nephrol., March 1, 2003; 14(3): 721 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mourad, J. Malaise, D. Chaib Eddour, M. De Meyer, J. Konig, R. Schepers, J. P. Squifflet, and P. Wallemacq Pharmacokinetic Basis for the Efficient and Safe Use of Low-Dose Mycophenolate Mofetil in Combination with Tacrolimus in Kidney Transplantation Clin. Chem., July 1, 2001; 47(7): 1241 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Meeus, T. Messiaen, G. Verhoef, and Y. Vanrenterghem New-onset anaemia following kidney transplantation Nephrol. Dial. Transplant., December 1, 2000; 15(12): 2059 - 2061. [Full Text] [PDF]
|
|
|
|
|
|
B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER Recommendations for the Outpatient Surveillance of Renal Transplant Recipients J. Am. Soc. Nephrol., October 1, 2000; 11 (90001): S1 - S86. [Abstract] [Full Text] [PDF]
|
|